CytomX News

CytomX Therapeutics Analyst Ratings

BenzingaNov 11, 2024 22:40

H.C. Wainwright Maintains CytomX(CTMX.US) With Hold Rating

Futu NewsNov 11, 2024 20:34

Piper Sandler Maintains CytomX(CTMX.US) With Buy Rating, Cuts Target Price to $3.25

Futu NewsNov 9, 2024 00:31

Barclays Maintains CytomX(CTMX.US) With Buy Rating, Maintains Target Price $3.5

Futu NewsNov 8, 2024 18:37

CytomX Therapeutics (CTMX) Receives a Buy From Barclays

TipRanksNov 8, 2024 17:43

H.C. Wainwright Maintains CytomX(CTMX.US) With Hold Rating

Futu NewsSep 13, 2024 18:31

H.C. Wainwright Sticks to Their Hold Rating for CytomX Therapeutics (CTMX)

TipRanksSep 13, 2024 18:20

Analysts Offer Insights on Healthcare Companies: BioCardia (BCDA) and CytomX Therapeutics (CTMX)

TipRanksAug 22, 2024 21:22

CytomX Therapeutics Analyst Ratings

BenzingaAug 22, 2024 19:34

H.C. Wainwright Maintains CytomX(CTMX.US) With Hold Rating

Futu NewsAug 22, 2024 18:31

CytomX Therapeutics (CTMX) Receives a Buy From Barclays

TipRanksAug 9, 2024 15:54

CytomX Therapeutics Analyst Ratings

BenzingaJun 27, 2024 18:35

CytomX Therapeutics Analyst Ratings

BenzingaMay 28, 2024 17:35

Piper Sandler Upgrades CytomX Therapeutics to Overweight, Raises Price Target to $3.5

BenzingaMay 28, 2024 17:35

BMO Capital Maintains Market Perform on CytomX Therapeutics, Raises Price Target to $3.59

BenzingaMay 9, 2024 22:55

HC Wainwright & Co. : The CytomX Therapeutics (CTMX.US) neutral rating was reaffirmed.

Zhitong FinanceMay 9, 2024 22:10

Wedbush: Upgraded CytomX Therapeutics (CTMX.US) rating from neutral to better than the market rating, and adjusted the target price from $3.00 to $8.00.

Zhitong FinanceMay 9, 2024 21:12

CytomX Therapeutics Analyst Ratings

BenzingaMay 9, 2024 21:10

Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3

MT NewswiresMay 9, 2024 19:51

Barclays Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)

TipRanksMay 9, 2024 15:30